ORIC Pharmaceuticals
South San Francisco, California, United StatesFounded 2014129+ employeesORIC
$533M raisedIPO· last: post ipo equity (May 2025)· 8 rounds
Backed by(32 investors)
SR One · LeadNextech Invest · LeadArrowMark Partners · LeadFidelity · LeadInvus · LeadPfizer · LeadThe Column Group · Lead+8 more
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) Enozertinib (ORIC-114), a brain penetrant inhibitor designed to selectively target EGFR exon 20, HER2 exon 20 and EGFR atypical mutations in NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.
